Rapid Result Antigen Home Test Kit 99% Accuracy Neutralizing Antibody

Class III 15-20 Minutes SARS-CoV-2 Antigen Home Test Set Neutralizing Antibody 1 test/box

Features

15-minute rapid detection

Easy-to-operate coronavirus antigen test

Less-invasive nasal (NS) swab sample collection

CE-IVD marked

Available in 1/2/5/20 tests/box

Nasopharyngeal swab and saliva versions available

The latest innovation in coronavirus testing allows detection of current coronavirus infection from a swab or saliva sample in minutes. No laboratory analysis is required.

Description

SARS-CoV-2 Antigen Test is intended for use by clinical laboratory personnel specifically instructed on in vitro diagnostic procedures. The SARS-CoV-2 Antigen Test is only for use under the Food and Drug Administration’s Emergency Use Authorization.

Date sheet

Advantages of Antigen Rapid Test

Although the development cycle of antigen detection is relatively long, its
1.Sensitivity and specificity are higher than antibody detection
2.The pathogen can be detected at the initial stage of infection
3.Short TAT and simple operation.
4.No professional technicians and equipment are required, and the test can be completed in 15 min.
5.Home use.
6.Personal test.

Jiangsu iiLO Biotechnology Co., Ltd. is located in Xukou Town, Wuzhong District, Suzhou City, Jiangsu Province. Suzhou is 100 kilometers away from Shanghai and 200 kilometers away from Nanjing. It is in the center of the Yangtze River Delta Economic Belt. Our main business covers two major sudivisions: BioScience and BioMedicine, including scientific instruments and life science reagents research, medical equipments and diagnostic reagents. From R&D to production and the marketing promotion of products.
We have maintained good business relationship with more than 100 biotechnology companies and customers both domestic and abroad.Our key domestic account including Nanjing University, Wuhan Institute of Virology CAS, etc. And our answering product --disposable collectors (saliva) have been exported to Hong Kong, Southeast Asia, Australia and North America.